Previous Close | 82.01 |
Open | 82.79 |
Bid | 75.00 x 1000 |
Ask | 84.04 x 800 |
Day's Range | 80.55 - 82.79 |
52 Week Range | 72.58 - 180.43 |
Volume | |
Avg. Volume | 567,743 |
Market Cap | 4.521B |
Beta (5Y Monthly) | 1.21 |
PE Ratio (TTM) | 9.10 |
EPS (TTM) | 7.01 |
Earnings Date | Nov 02, 2022 |
Forward Dividend & Yield | 2.64 (2.97%) |
Ex-Dividend Date | May 26, 2022 |
1y Target Est | 92.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for SMG
Its cannabis-related subsidiary, The Hawthorne Gardening Company, continues to suffer from overcapacity in the industry, and its sales declined a whopping 63%. In fact, the overall company's sales were so weak that it left the company with "higher leverage than we want to maintain," according to CEO Jim Hagedorn on the earnings release. As a reminder, the financial world typical gauges debt levels on the basis of earnings, so as its earnings outlook gets worse, so will Scotts come under pressure to reduce debt.
Scotts Miracle-Gro (SMG) sees lower-than-expected sales in the U.S. Consumer segment and sustained pressure on sales in the Hawthorne unit in Q3.
Key Takeaways; Cannabis Sector Cannabis REIT IIPR generated record revenue of $70.5 million in the second quarter. Green Thumb Q2 revenue increased 5%, to $254 million. Scotts Miracle-Gro share price soared, despite the company missing earnings estimates. Key Takeaways; Psychedelic Sector Awakn received CA$2.5 government funding for phase III trial. July was a great month […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.